Infectious Disease Diagnostic Market size is expanding as the epidemiological burden of infectious diseases continues to rise globally. Infectious diseases are among the leading causes of morbidity and death. The recent outbreak of the COVID-19 pandemic has also augmented the demand for various POC diagnostic test kits to control the spread of the coronavirus.
Diagnostics is the first and most important step for disease discovery and treatment and ongoing scientific research and development is changing the way rapid diagnostics are being performed. Ongoing technological developments will continue to change the landscape of industry over the forecast period.
In terms of technology, the polymerase chain reaction (PCR) segment in the infectious disease diagnostic market has witnessed tremendous growth in 2020, mainly due to the rapid spread of the coronavirus pandemic. The use of reverse transcription polymerase chain reaction (RT-PCR) diagnostic tests across the world has surged rapidly since the COVID-19 outbreak. Sustained nature of the pandemic and the emergence of new variants mean that PCR diagnostic solutions will continue to be in demand in the coming years.
The hepatitis diagnostics market share is slated to grow substantially by 2027. The WHO reports that more than 500 million individuals suffer from Hepatitis globally. Growing number of blood donations and transfusions is a primary cause of the disease, which can be prevented if diagnosed in the early stages. High susceptibility of the geriatric population and increasing awareness about Hepatitis among the public will continue to drive the demand for hepatitis diagnostic solutions.
In January 2021, the WHO announced plans to boost the number of registered treatments and reduce costs of full treatment as part of its efforts to accelerate access to Hepatitis C diagnostics and treatment in low- and middle-income countries. In June, WHO also released a global guidance for country validation as part of its agenda to eliminate viral hepatitis as a public health problem by 2030. These factors will play a crucial role in fueling the demand for hepatitis diagnostics.
North America infectious disease diagnostic market is set to register appreciable gains during the forecast timeframe led by increasing investment by the government and healthcare sector towards infrastructure, improvement, and the need to address the rising infectious disease burden. The regional governments have undertaken numerous efforts to improve the accessibility of diagnostic services. Changing regulatory landscape mandating infectious disease testing will positively influence the regional outlook.
In July 2021, the state of Colorado, U.S., had announced a USD 173 million federal funding to expand COVID-19 testing in schools during 2021-2022, even as restrictions are lifted. The announcement was made following reports of the new Delta variant spreading across the state. The state is looking for companies that can deliver COVID-19 rapid antigen tests as well as the more sensitive RT-PCR tests.
Globally, Abbott Laboratories, Bio-Rad Laboratories, Becton Dickinson, Danaher Corporation, Thermo Fisher Scientific, Siemens AG, Roche Diagnostics, Meridian Bioscience, Luminex, Diasorin , Biomérieux SA, and Quidel are some of the leading developers of infectious disease diagnostic market. In March 2021, Abbott Laboratories had launched the Pandemic Defense Coalition to detect future variants and potentially dangerous mutations of viruses. The company had launched a network of centers with expertise in public health, genetic sequencing, and lab testing to develop diagnostic tests for new variants of COVID-19, Hepatitis, HIV, malaria, and other diseases.
Diagnostic testing has been one of the most important tools in understanding and handling the worldwide COVID-19 pandemic. At the start of the pandemic, respective governments and public health organizations had announced new funding to provide healthcare providers and laboratories access to testing kits. In April 2020, for instance, the European Institute of Innovation and Technology (EIT) Health had announced a funding of USD 7.6 million and launched the Rapid Response initiative to foster diagnostic testing capacity.
The pandemic also showcased diagnostic test manufacturers ramp up production of rapid testing kits for laboratories as well as easy-to-use devices to facilitate testing outside of laboratory settings. For example, in June 2021, Abbott received CE Marking for its Panbio rapid antigen test kit which can be used by European consumers at home. The demand for diagnostic solutions will continue to grow in the near future will new COVID-19 cases still emerging in numerous regions, which will positively propel the infectious disease diagnostic market growth over 2021-2027.
Market By Product & Services, 2013-2024 (USD Million)
Market By Technology, 2013-2024 (USD Million)
Market By Disease Type, 2013-2024 (USD Million)
Market By End-use, 2013-2024 (USD Million)
The above information is provided for the following regions and countries: